Objective： To study the curative efficacy of losartan combined with cyclic adenosine monophosphate in the treatment of pulmonary heart disease and the serum levels of IL-2, slL-2R and 8-iso-PG. Methods： 94 patients with pulmonary heart disease who were treated from September 2010 to September 2015 were selected and randomly divided into the observation group and the control group with 47 cases in each group. The control group was treated with conventional treatment of pulmonary heart disease, while the ob- servation group was treated with losartan and cyclic adenosine monophosphate on the basis of control group. Then the cardiac function, pulmonary function, immune function, serum levels of IL-2, slL-2R and 8-iso-PG and curative effect in the two groups were observed and compared before and after the treatment. Results： After treatment, the cardiac function improved in both groups （P〈0.05）; The levels of CO, LVEF, SV, FEV1 and FEV1 / FVC in the observation group were higher than those of the control group [（5.21± 0.27） vs （4.15± 0.46）,（63.42± 6.17） vs （52.37± 5.76）,（74.68± 9.24） vs （64.56± 11.73）,（1.75± 0.27） vs （1.32± 0.31）,（75.68± 10.62） vs （65.49± 10.05）] （P〈0.05）; The complement C3 level of observation group was higher than that of the control group[（1.34± 0.12） g/L vs（1.16± 0.10） g/L] （P〈0.05）; The levels of slL-2R and 8-iso-PG of observation group were lower than those of the control group [（371.46± 161.06） U/ml vs（435.75 ± 152.43） U/ml, （23.58 ± 11.72） ng/L vs（31.08 ± 11.39） ng/L] （P〈0.05）. The total effective rate of observation group was higher than that of the control group [95.74% vs78.72%] （P〈0.05）. Conclusion： Losartan combined with adenosine cyclophosphamide could improve the heart, lung and immune function, enhance the level of complement C3, and improve the symptoms of ischemia and hypoxia. [ABSTRACT FROM AUTHOR]